Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP,Global Marketing&Portfolio | March 03, 2023 | March 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date March 03, 2023 · Filed March 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 54,228 |
Last balance in matching sequence
After 2023-03-05 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-03-04 · Exercise / conversion · Acquired 3,173 · Balance 28,225 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 2 · 2023-03-04 · Exercise / conversion · Acquired 20,107 · Balance 48,332 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Row 3 · 2023-03-05 · Exercise / conversion · Acquired 5,896 · Balance 54,228 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 59,760 |
Reported balance
After 2023-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-03 · Grant · Acquired 59,760 · Balance 59,760 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-04 · Exercise / conversion · Disposed 3,173 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4: Restricted share units were granted on March 4, 2019, with 3,173 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 60,321 |
Reported balance
After 2023-03-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-04 · Exercise / conversion · Disposed 20,107 · Balance 60,321 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 11,794 |
Reported balance
After 2023-03-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-05 · Exercise / conversion · Disposed 5,896 · Balance 11,794 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6: Restricted share units were granted on March 5, 2021, with 5,896 vested on each of March 5, 2022 and March 5, 2023, 5,896 vesting on March 5, 2024, and 5,898 vesting on March 5, 2025. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027.
F4: Restricted share units were granted on March 4, 2019, with 3,173 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023.
F5: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.
F6: Restricted share units were granted on March 5, 2021, with 5,896 vested on each of March 5, 2022 and March 5, 2023, 5,896 vesting on March 5, 2024, and 5,898 vesting on March 5, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · derivative · entry 7 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,794 Underlying: Ordinary Shares · 5,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 5,896 vested on each of March 5, 2022 and March 5, 2023, 5,896 vesting on March 5, 2024, and 5,898 vesting on March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 5,896 vested on each of March 5, 2022 and March 5, 2023, 5,896 vesting on March 5, 2024, and 5,898 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · nonDerivative · entry 3 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · derivative · entry 6 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,321 Underlying: Ordinary Shares · 20,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 20,107 vested on March 4, 2023, and 20,107 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · derivative · entry 5 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 3,173 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 3,173 vested on each of March 4, 2021, March 4, 2022, and March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · nonDerivative · entry 2 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · nonDerivative · entry 1 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 59,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016719 · doc4.xml · derivative · entry 4 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,760 Underlying: Ordinary Shares · 59,760 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 14,940 vesting on each of March 3, 2024, March 3, 2025, March 3, 2026, and March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014441 · doc4.xml · derivative · entry 2 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,312 Underlying: Ordinary Shares · 5,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 5,311 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 5,312 vesting on February 28, 2024. F3 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 5,311 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 5,312 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 12:37 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,311 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014441 · doc4.xml · nonDerivative · entry 1 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 11:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 1,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045351 · doc4.xml · derivative · entry 2 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on August 10, 2018, with 1,581 vesting on August 10, 2022. F3 · derivative.expiration_date: Restricted share units were granted on August 10, 2018, with 1,581 vesting on August 10, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 11:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 1,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-045351 · doc4.xml · nonDerivative · entry 1 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017061 · doc4.xml · derivative · entry 5 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,690 Underlying: Ordinary Shares · 5,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 5,896 having vested on March 5, 2022, 5,896 vesting on each of March 5, 2023 and March 5, 2024, and 5,898 vesting on March 5, 2025. F5 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 5,896 having vested on March 5, 2022, 5,896 vesting on each of March 5, 2023 and March 5, 2024, and 5,898 vesting on March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2022 Filed Mar 8, 2022 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017061 · doc4.xml · nonDerivative · entry 2 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 80,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017061 · doc4.xml · derivative · entry 4 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,428 Underlying: Ordinary Shares · 80,428 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 20,107 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017061 · doc4.xml · derivative · entry 3 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173 Underlying: Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023. F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:13 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-017061 · doc4.xml · nonDerivative · entry 1 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 5,311 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014474 · doc4.xml · derivative · entry 3 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,623 Underlying: Ordinary Shares · 5,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 5,311 having vested on each of February 28, 2021 and February 28, 2022, 5,311 vesting on February 28, 2023 and 5,312 vesting on February 28, 2024. F4 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 5,311 having vested on each of February 28, 2021 and February 28, 2022, 5,311 vesting on February 28, 2023 and 5,312 vesting on February 28, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 5,311 | $8.14 | $43,243.22 |
DisclosureSEC source: 0001209191-22-014474 · doc4.xml · nonDerivative · entry 2 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,091 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 12:53 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 5,311 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-014474 · doc4.xml · nonDerivative · entry 1 Shani Eli · CIK 0001876642 · EVP,Global Marketing&Portfolio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.